CanSino Biologics (HKG:6185, SHA:688185) said its Phase I/II clinical trial for the Recombinant Poliomyelitis Vaccine ("CS-2036") was officially initiated in Indonesia recently, with the first trial patient case of the Phase I clinical trial being formally enrolled, according to a Friday filing with the Hong Kong bourse.
The CS-2036 is a polio treatment, a non-infectious polio vaccine developed using advanced protein design and virus-like particle (VLP) technology.
The pharmaceutical stocks were down by over 1% on the Hong Kong bourse and over 2% on the Shanghai Stock Exchange in recent trading.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。